Differentially Expressed Genes Identify FIGO Stage II Cervical Cancer Patients with a Higher Risk of Relapse in a Small Cohort

<b>Background/Objectives</b>: Most studies investigating prognostic biomarkers in cervical cancer (CC) analyze patients irrespective of FIGO stage, potentially masking molecular features that underlie the aggressiveness of some FIGO II tumors. To address this, we investigated differential gene expression in a FIGO II CC cohort to identify a gene signature predictive of progression-free survival (PFS) within five years of treatment initiation. <b>Methods</b>: Tumor samples from 15 CC patients were analyzed using RNA sequencing, bioinformatics, and machine learning to identify differentially expressed genes (DEGs) associated with prognosis. Findings were validated in an independent CC cohort (<i>n</i> = 174). <b>Results</b>: High expression of B3GALT1 (HR = 5.11), GTF3C2-AS1 (HR = 18.73), and ZKSCAN4 (HR = 5.18) was significantly associated with an increased risk of recurrence in our cohort. Elevated expression of these transcripts is also associated with shorter PFS in the external dataset. Notably, GTF3C2-AS1 expression alone was sufficient to classify all fifteen patients into their respective prognostic groups using a decision tree model, achieving 93.3% accuracy in leave-one-out cross-validation (LOOCV). Additional candidates, including RCAN2-DT, MYH9-DT, IGKC, IGHG1, and IGHG3, were associated with PFS in our cohort but could not be externally validated due to a lack of available data. <b>Conclusions</b>: Transcriptomic profiling revealed potential biomarkers that refine prognostic stratification in cervical cancer beyond FIGO staging. Among them, GTF3C2-AS1 consistently emerged as a potential predictor of recurrence risk. Additional candidates, including B3GALT1, ZKSCAN4, and immunoglobulin transcripts, provided complementary insights but require further validation. These preliminary results highlight intra-stage heterogeneity in FIGO II CC and underscore the promise of molecular markers to improve risk assessment.

Authors

Institutions

Publication Details

Journal
Journal of Personalized Medicine
Published
2025-10-16
DOI
https://doi.org/10.3390/jpm15100497
Primary Topic
Cancer-related molecular mechanisms research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Differentially Expressed Genes Identify FIGO Stage II Cervical Cancer Patients with a Higher Risk of Relapse in a Small Cohort

Letícia da Conceição Braga, Laurence Rodrigues do Amaral, Carolina Pereira de Souza Melo, A.B. De Biase Bezerra de Melo et al.
Journal of Personalized Medicine
Cancer-related molecular mechanisms research
article

Differentially Expressed Genes Identify FIGO Stage II Cervical Cancer Patients with a Higher Risk of Relapse in a Small Cohort

Letícia da Conceição Braga, Laurence Rodrigues do Amaral, Carolina Pereira de Souza Melo, A.B. De Biase Bezerra de Melo, Jorge G. Ferreira, Wander de Jesus Jeremias, Paulo Guilherme de Oliveira Salles, Fábio Ribeiro Queiroz, Pedro Luiz Lima Bertarini, Izabela Ferreira Gontijo de Amorim, Matheus de Souza Gomes, Ramon A. Pereira, Álvaro Percínio Costa
article en

Abstract

<b>Background/Objectives</b>: Most studies investigating prognostic biomarkers in cervical cancer (CC) analyze patients irrespective of FIGO stage, potentially masking molecular features that underlie the aggressiveness of some FIGO II tumors. To address this, we investigated differential gene expression in a FIGO II CC cohort to identify a gene signature predictive of progression-free survival (PFS) within five years of treatment initiation. <b>Methods</b>: Tumor samples from 15 CC patients were analyzed using RNA sequencing, bioinformatics, and machine learning to identify differentially expressed genes (DEGs) associated with prognosis. Findings were validated in an independent CC cohort (<i>n</i> = 174). <b>Results</b>: High expression of B3GALT1 (HR = 5.11), GTF3C2-AS1 (HR = 18.73), and ZKSCAN4 (HR = 5.18) was significantly associated with an increased risk of recurrence in our cohort. Elevated expression of these transcripts is also associated with shorter PFS in the external dataset. Notably, GTF3C2-AS1 expression alone was sufficient to classify all fifteen patients into their respective prognostic groups using a decision tree model, achieving 93.3% accuracy in leave-one-out cross-validation (LOOCV). Additional candidates, including RCAN2-DT, MYH9-DT, IGKC, IGHG1, and IGHG3, were associated with PFS in our cohort but could not be externally validated due to a lack of available data. <b>Conclusions</b>: Transcriptomic profiling revealed potential biomarkers that refine prognostic stratification in cervical cancer beyond FIGO staging. Among them, GTF3C2-AS1 consistently emerged as a potential predictor of recurrence risk. Additional candidates, including B3GALT1, ZKSCAN4, and immunoglobulin transcripts, provided complementary insights but require further validation. These preliminary results highlight intra-stage heterogeneity in FIGO II CC and underscore the promise of molecular markers to improve risk assessment.

Journal of Personalized MedicineVol. 15(10)
Universidade Federal de Ouro Preto (BR), Universidade Federal de Minas Gerais (BR), Translational Research in Oncology (FR), Universidade Federal de Uberlândia (BR)
Openalex Percentile: Top 64%
Cancer-related molecular mechanisms research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.